Implementation of a seamless phase 2/3 study design in the setting of an emergent infectious disease pandemic: Lessons learned from the ACTIV-2 platform COVID-19 treatment trial

By sjmartinez • March 28, 2025

Giganti MJ, Chew KW, Moser C, Eron JJ, Pinilla M, Li JZ, Ritz J, Javan AC, Wohl DA, Daar ES, Currier JS, Smith DM, Hughes MD; ACTIV-2/A5401 Study Team. Implementation of a seamless phase 2/3 study design in the setting of an emergent infectious disease pandemic: Lessons learned from the ACTIV-2 platform COVID-19 treatment trial. Contemp Clin Trials. 2025 Mar 25:107887. doi: 10.1016/j.cct.2025.107887. Epub ahead of print. PMID: 40147543.

Tags: Bayesian, covid-19, Go/No-Go, Graduation, Harbor UCLA, Infectious Diseases, Phase 2/3, Platform, Publications, Seamless

Design and Rationale of the WARRIOR Ancillary Study for Coronary CT Angiographic Analysis

Tamarappoo B, Wolny R, Tomasino GF, Berman D, Handberg E, Pepine CJ, Lo MC, Budoff M, Shaw L, Shufelt C, Wei J, Gulati M, Merz[...]

Ethnic differences in left ventricular myocardial volume assessed by coronary computed tomography angiography in asymptomatic adults

Zahraee S, Beshoy I, Kinninger A, Mao SS, Budoff MJ. Ethnic differences in left ventricular myocardial volume assessed by coronary computed tomography angiography in asymptomatic[...]

Can chlorhexidine bathing reduce Candidozyma auris shedding?

Gussin GM, Singh RD, Kleinman K, Saavedra R, Shimabukuro JA, Flores EA, Miller LG, Bittencourt CE, Huang SS. Can chlorhexidine bathing reduce Candidozyma auris shedding?[...]